-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
From July 2nd to 3rd, 2021, the "2021 China Clinical Oncology Annual Progress Seminar (BOC) and Best of ASCO® 2021 China" was successfully held in Chengdu, the land of abundance
.
The conference invited domestic oncology experts from various fields to comment on the wonderful research in the 2021 ASCO meeting; at the same time, there is a Chinese clinical oncology annual progress report link, which is selected by CSCO for the 2020 Chinese clinical oncology annual progress and Chinese experts’ international The clinical research of the conference report was summarized and discussed
.
At this meeting, Yimaitong invited Professor Ma Jun and Professor Zhao Donglu from Harbin Institute of Hematology and Tumor and Professor Ying Zhitao from Peking University Cancer Hospital to interpret the relevant progress in the field of lymphoma
.
Yimaitong: What are the research developments in the field of lymphoma that deserve attention in recent years? What are the unresolved problems? Professor Ma Jun has made four major advances in the field of lymphoma in recent years.
The first is in small molecule drugs.
There are currently 146 small molecule drugs in clinical use
.
Secondly, in terms of antibody drugs, in addition to monoclonal antibodies, the clinical results of bi-Mabs, poly-Mabs, and antibody-drug conjugates (ADC) are all gratifying.
There are already more than 100 antibody drugs available
.
Third, in terms of cellular immunotherapy, such as CAR-T and CAR-NK have also achieved good results
.
Fourth, in terms of the clinical application of PD-1 inhibitors and PD-L1 inhibitors, since the domestic approval of pembrolizumab and nivolizumab, there are currently six Chinese PD-1 inhibitors and PD -L1 inhibitors are used in lymphoma and other solid tumors, and the cost has also been reduced, benefiting the public
.
It is worth mentioning that recently, Akilunza has been formally approved by the National Medical Products Administration (NMPA) and has become the only CAR-T cell therapy approved in China.
This is a major breakthrough in the field of cancer treatment in China
.
CAR-T cell therapy is an innovative therapy in the field of lymphoma.
It has achieved good results in relapsed and refractory B-cell lymphoma and other types of lymphoma, and may even achieve a clinical cure
.
The treatment of lymphoma in China is progressing rapidly, new drugs are coming out, and the survival period of patients is gradually prolonged, but there are still some problems and challenges
.
The level of diagnosis and treatment in domestic basic-level hospitals and non-hematological lymphoma hospitals still needs to be improved.
Although the five-year cure rate of Beijing, Shanghai and Guangzhou lymphoma can reach more than 60%, the five-year survival rate of 16,898 lymphoma patients is only 37.
2.
%, it can be seen that standardized treatment is very important
.
Therefore, there is an urgent need to improve the level of diagnosis and treatment in primary hospitals, communities, and individual clinics so that patients can receive the best treatment
.
Yimaitong: China's first CAR-T drug was recently approved for marketing.
What kind of changes do you think this will bring to the treatment of patients with relapsed and refractory lymphoma in China? Professor Donglu Zhao’s CAR-T cell therapy, Akilensay, was officially approved by the NMPA recently, providing a better treatment for patients with diffuse large B-cell lymphoma (DLBCL), especially for relapsed and refractory patients
.
International studies have shown that patients with indolent lymphomas such as mantle cell lymphoma, follicular lymphoma, or marginal zone lymphoma can also benefit from CAR-T cell therapy.
It is expected that CAR-T cell therapy can bring more patients Come to a longer life span
.
Professor Ying Zhitao has been developing CAR-T cells for more than ten years and has achieved very good curative effects in the field of tumors, especially in the field of hematological tumors
.
In patients with relapsed and refractory large B-cell lymphoma, multiple myeloma, and acute lymphoblastic leukemia, CAR-T cell therapy is more effective than other existing treatment methods
.
The approval of the first domestic CAR-T cell drug Aquilense is a milestone, representing China's official entry into the era of cell therapy
.
Yimaitong: How do you think the recent approval of many new drugs and therapies will bring about changes in the diagnosis and treatment of lymphoma? Professor Zhao Donglu has seen an endless stream of new drugs in the field of lymphoma in recent decades, especially for patients with relapse and refractory treatment
.
In recent years, the clinical application of non-chemotherapeutic combinations of new drugs has been gratifying.
For example, the combination of BCL-2 inhibitors, BTK inhibitors, PI3K inhibitors and CD20 monoclonal antibodies is not only in chronic lymphocytic leukemia, but also in chronic lymphocytic leukemia.
Very good curative effects have also been obtained in indolent lymphoma, and a longer survival period has been achieved for patients with relapsed and refractory disease
.
In some aggressive lymphomas, such as DLBCL and T-cell lymphoma, there are also non-chemotherapeutic combinations currently being explored
.
We look forward to the continuous progress of more therapeutic drugs and programs to provide patients with lymphoma with better survival benefits and quality of life
.
Yimaitong: What are your prospects for the treatment of hematological tumors? From the earliest radiotherapy and chemotherapy, to the first targeted therapy drug CD20 monoclonal antibody, to small molecule targeted drugs, to the current cellular immunotherapy, he started his exploration in the field of hematological tumors
.
In general, hematological tumors have been leading the progress and direction of new drug treatments in the entire tumor field, and have very good therapeutic prospects, including patients who have been considered to be ineffective or incurable in the past, and they can also be cured by some new drug treatments
.
Professor Ma Jun Chief Physician, Professor, and Doctoral Supervisor Director of Harbin Institute of Hematological Oncology, Chairman of the Supervisory Board of the Chinese Society of Clinical Oncology (CSCO) Vice Chairman of the Asian Society of Clinical Oncology, Chairman of the CSCO Anti-Leukemia Alliance Former Deputy Director of the Hematology Branch of the Chinese Medical Association Committee Member, Chinese Medical Doctor Association, Hematologists Branch Vice President, Chinese Medical Doctor Association Oncology Branch Vice President, CSCO Anti-Lymphoma Alliance Former Chairman, Professor Zhao Donglu, Assistant Director of Harbin Institute of Hematology and Tumors, Assistant Director of the Fourth Blood Ward (Lymphatic System Diseases), Chinese Medical Association Blood Deputy head of the Lymphocytic Diseases Group of the Chinese Society of Clinical Oncology (CSCO) Deputy Secretary-General of the CSCO Anti-Lymphoma Alliance Expert Committee Deputy Secretary-General of the CSCO Anti-Lymphoma Alliance Child and Adolescent Lymphoma Group Member CSCO Youth Expert Committee Member China Anti-Lymphoma Alliance Young Member of the Hematology Oncology Committee of the Cancer Society Member of the Lymphoma Group of the Hematology Branch of the Chinese Geriatrics Association Member of the Lymphoma Group of the Hematology Branch of the Chinese Medical Association Professor Ying Zhitao Doctor of Medicine, Peking University Cancer Hospital, Associate Chief Physician, China Anti-Cancer Association Hematology Oncology Committee Youth Committee Member, Chinese Geriatric Hematology Lymphoma Group Member, Chinese Medical Association Oncology Branch Youth Committee Member, Chinese Society of Clinical Oncology (CSCO) Youth Expert Committee Member, Chinese Geriatric Healthcare Association Drug Clinical Research and Evaluation Committee Member, the main research direction is Standardized diagnosis and treatment of lymphoma.
Participated in the compilation of many oncology books and published more than 20 papers.
"Read the original text", and we will make progress together
.
The conference invited domestic oncology experts from various fields to comment on the wonderful research in the 2021 ASCO meeting; at the same time, there is a Chinese clinical oncology annual progress report link, which is selected by CSCO for the 2020 Chinese clinical oncology annual progress and Chinese experts’ international The clinical research of the conference report was summarized and discussed
.
At this meeting, Yimaitong invited Professor Ma Jun and Professor Zhao Donglu from Harbin Institute of Hematology and Tumor and Professor Ying Zhitao from Peking University Cancer Hospital to interpret the relevant progress in the field of lymphoma
.
Yimaitong: What are the research developments in the field of lymphoma that deserve attention in recent years? What are the unresolved problems? Professor Ma Jun has made four major advances in the field of lymphoma in recent years.
The first is in small molecule drugs.
There are currently 146 small molecule drugs in clinical use
.
Secondly, in terms of antibody drugs, in addition to monoclonal antibodies, the clinical results of bi-Mabs, poly-Mabs, and antibody-drug conjugates (ADC) are all gratifying.
There are already more than 100 antibody drugs available
.
Third, in terms of cellular immunotherapy, such as CAR-T and CAR-NK have also achieved good results
.
Fourth, in terms of the clinical application of PD-1 inhibitors and PD-L1 inhibitors, since the domestic approval of pembrolizumab and nivolizumab, there are currently six Chinese PD-1 inhibitors and PD -L1 inhibitors are used in lymphoma and other solid tumors, and the cost has also been reduced, benefiting the public
.
It is worth mentioning that recently, Akilunza has been formally approved by the National Medical Products Administration (NMPA) and has become the only CAR-T cell therapy approved in China.
This is a major breakthrough in the field of cancer treatment in China
.
CAR-T cell therapy is an innovative therapy in the field of lymphoma.
It has achieved good results in relapsed and refractory B-cell lymphoma and other types of lymphoma, and may even achieve a clinical cure
.
The treatment of lymphoma in China is progressing rapidly, new drugs are coming out, and the survival period of patients is gradually prolonged, but there are still some problems and challenges
.
The level of diagnosis and treatment in domestic basic-level hospitals and non-hematological lymphoma hospitals still needs to be improved.
Although the five-year cure rate of Beijing, Shanghai and Guangzhou lymphoma can reach more than 60%, the five-year survival rate of 16,898 lymphoma patients is only 37.
2.
%, it can be seen that standardized treatment is very important
.
Therefore, there is an urgent need to improve the level of diagnosis and treatment in primary hospitals, communities, and individual clinics so that patients can receive the best treatment
.
Yimaitong: China's first CAR-T drug was recently approved for marketing.
What kind of changes do you think this will bring to the treatment of patients with relapsed and refractory lymphoma in China? Professor Donglu Zhao’s CAR-T cell therapy, Akilensay, was officially approved by the NMPA recently, providing a better treatment for patients with diffuse large B-cell lymphoma (DLBCL), especially for relapsed and refractory patients
.
International studies have shown that patients with indolent lymphomas such as mantle cell lymphoma, follicular lymphoma, or marginal zone lymphoma can also benefit from CAR-T cell therapy.
It is expected that CAR-T cell therapy can bring more patients Come to a longer life span
.
Professor Ying Zhitao has been developing CAR-T cells for more than ten years and has achieved very good curative effects in the field of tumors, especially in the field of hematological tumors
.
In patients with relapsed and refractory large B-cell lymphoma, multiple myeloma, and acute lymphoblastic leukemia, CAR-T cell therapy is more effective than other existing treatment methods
.
The approval of the first domestic CAR-T cell drug Aquilense is a milestone, representing China's official entry into the era of cell therapy
.
Yimaitong: How do you think the recent approval of many new drugs and therapies will bring about changes in the diagnosis and treatment of lymphoma? Professor Zhao Donglu has seen an endless stream of new drugs in the field of lymphoma in recent decades, especially for patients with relapse and refractory treatment
.
In recent years, the clinical application of non-chemotherapeutic combinations of new drugs has been gratifying.
For example, the combination of BCL-2 inhibitors, BTK inhibitors, PI3K inhibitors and CD20 monoclonal antibodies is not only in chronic lymphocytic leukemia, but also in chronic lymphocytic leukemia.
Very good curative effects have also been obtained in indolent lymphoma, and a longer survival period has been achieved for patients with relapsed and refractory disease
.
In some aggressive lymphomas, such as DLBCL and T-cell lymphoma, there are also non-chemotherapeutic combinations currently being explored
.
We look forward to the continuous progress of more therapeutic drugs and programs to provide patients with lymphoma with better survival benefits and quality of life
.
Yimaitong: What are your prospects for the treatment of hematological tumors? From the earliest radiotherapy and chemotherapy, to the first targeted therapy drug CD20 monoclonal antibody, to small molecule targeted drugs, to the current cellular immunotherapy, he started his exploration in the field of hematological tumors
.
In general, hematological tumors have been leading the progress and direction of new drug treatments in the entire tumor field, and have very good therapeutic prospects, including patients who have been considered to be ineffective or incurable in the past, and they can also be cured by some new drug treatments
.
Professor Ma Jun Chief Physician, Professor, and Doctoral Supervisor Director of Harbin Institute of Hematological Oncology, Chairman of the Supervisory Board of the Chinese Society of Clinical Oncology (CSCO) Vice Chairman of the Asian Society of Clinical Oncology, Chairman of the CSCO Anti-Leukemia Alliance Former Deputy Director of the Hematology Branch of the Chinese Medical Association Committee Member, Chinese Medical Doctor Association, Hematologists Branch Vice President, Chinese Medical Doctor Association Oncology Branch Vice President, CSCO Anti-Lymphoma Alliance Former Chairman, Professor Zhao Donglu, Assistant Director of Harbin Institute of Hematology and Tumors, Assistant Director of the Fourth Blood Ward (Lymphatic System Diseases), Chinese Medical Association Blood Deputy head of the Lymphocytic Diseases Group of the Chinese Society of Clinical Oncology (CSCO) Deputy Secretary-General of the CSCO Anti-Lymphoma Alliance Expert Committee Deputy Secretary-General of the CSCO Anti-Lymphoma Alliance Child and Adolescent Lymphoma Group Member CSCO Youth Expert Committee Member China Anti-Lymphoma Alliance Young Member of the Hematology Oncology Committee of the Cancer Society Member of the Lymphoma Group of the Hematology Branch of the Chinese Geriatrics Association Member of the Lymphoma Group of the Hematology Branch of the Chinese Medical Association Professor Ying Zhitao Doctor of Medicine, Peking University Cancer Hospital, Associate Chief Physician, China Anti-Cancer Association Hematology Oncology Committee Youth Committee Member, Chinese Geriatric Hematology Lymphoma Group Member, Chinese Medical Association Oncology Branch Youth Committee Member, Chinese Society of Clinical Oncology (CSCO) Youth Expert Committee Member, Chinese Geriatric Healthcare Association Drug Clinical Research and Evaluation Committee Member, the main research direction is Standardized diagnosis and treatment of lymphoma.
Participated in the compilation of many oncology books and published more than 20 papers.
"Read the original text", and we will make progress together
